Keywords: Bayer, Xarelto, Visanne, VTE, Endometriosis, FDA, Europe, USA

Bayer says US filing for Xarelto delayed; Visanne cleared in Europe

Article | 07 December 2009

Print This

German drug major Bayer announced over the weekend details of data from the EINSTEIN Extension study for Xarelto (rivaroxaban), under ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in